This aspect led us to hypothesize that the diversity among CRC patients in basal PHGDH protein levels and its dynamic regulation along the treatment with 5-FU could result in differential therapy efficacy, finally influencing cancer progression and patients’ outcome. The gene discussed is PHGDH; the disease is cancer.